MHRA Approves Zanidatamab for HER2+ Biliary Tract Cancer
The MHRA has approved zanidatamab (Ziihera) for adult patients with HER2-positive biliary tract cancer that has progressed after previous treatment. This approval provides a new treatment option for a specific patient population with an unmet clinical need.
Priority review
Guidance
Pharmaceuticals